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Abstract 
This thesis comprises a collection of publications on new vaccines, vaccine safety and research in 
implementation of new vaccines into the community to inform public health policy globally. The papers 
presented outline my research experience in vaccinology which has been conducted in collaboration with a 
number of national and international colleagues, who are included as coauthors. I have been involved in all 
aspects of the research including study concepts, conduct, analysis and interpretation of the results and 
manuscript preparation and publication. 
Studies in investigational vaccines outlined in Chapters 1, 2 and 4 were conducted as multicentre studies 
on the immunogenicity and safety of new vaccines including DTPa·HBV·Hib (diphtheria, tetanus, acellular 
pertussis, hepatitis B and Haemophilus influenzae type b) vaccine, DTPa·HBV·IPV (diphtheria, tetanus, 
acellular pertussis, hepetHis B and inactivated polio) vaccine, live intranasal attenuated influenza vaccine, 
Hib-MenCY (Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y) vaccine, DTPa· 
IPV (diphtheria, tetanus, acellular pertussis and inactivated polio) vaccine, PIV3 (parainfluenza virus type 3) 
vaccine and RSV·PIV3 (respiratory syncytial virus and parainfluenza type 3 virus) vaccine. Many of these 
vaccines are now licensed in Australia (DTPa-HBV-IPV; "Infanrix-Penta", DTPa-IPV; "InfanrixIPV", HepAB; 
"Twinrix") with some licensed in other countries (live attenuated inlluenza vaccine; "RuMist'') and others 
soon to be licensed (Hib·MenCY) or still in clinical development (PIV3, RSV·PIV3). 
Licensing of vaccines has been dependent on provision of clinical data of an excellent standard, resutting 
from clinical studies conducted according to ICH·GCP (International Conlerence on Harmonisation - Good 
Clinical Practice) as included in this thesis. Currently, the cost of bringing a vaccine from the laboratory 
bench to the market is around $1 billion, with much of this cast derived from extensive clinical trial testing 
undertaken, oiten directed or influenced by regulatory authorities. 
Studies for neonates, yaung children and adolescents require specific approaches relevant to their needs. 
Important areas such as recruitment to studies, levels of understanding, needs of families and caregivers, 
and appropriate care of potentially fearful and tearful partiCipants all need to be addressed carefully and 
with great skill and support. Issues of assessment of symptoms and potential adverse effects need to be 
approached differently to those in older independent study participants. Paediatric vaccine clinical trials 
can only be successfully conducted with a specialized, experienced and dedicated team of investigators 
with a wide range of individual skills. Each investigational participant age group requires a specific type of 
specialist expertise, including skills which may range from venesection of a 2 month old infant (preferably 
on the first attempt), to blowing bubbles to distract an anxious 4 year old being vaccinated to discussing the 
study requirement for urine pregnancy testing (as part of study exclusion criteria) to a 12 year old girl. The 
successful completion of a paediatric vaccine study is dependent on staff that can provide ethical 
judgement and the required support and consideration for families that are willing to be involved in 
vaccinology research for the public good. There are only a select group of paediatric vaccinology centres 
in Australia of which our unit is included. Conducting investigational vaccine trials in Australia has the 
advantage of providing immunogenicity and safety data in Australian children to Australian regulatory 
authorities and immunisation expert groups such as the Australian Technical Advisory Group on 
Immunisation (ATAGI) to inform the optimal immunisation schedule for the Australian population. 
Community engagement in and acceptance of new vaccines introduced into the community underpins the 
success of immunisation programs. Resutts of social epidemiological studies conducted to examine the 
introduction of vaccines including varicella, human papillomavirus, and pandemic influenza vaccines are 
outlined in Chapter 3. Understanding community awareness of vaccines and concerns about vaccine 
safety is essential for the planning and development of vaccine delivery programs whether delivered 
through schools, doctors or local government. Results of these studjes showed low knowledge of Human 
Papillomavirus disease and vaccination in the community but acceptance of this cancer preventing strategy 
if the vaccine was deemed to be sate. Ukewise knowledge of pandemic influenza was poor but 
acceptance of strategies to prevent transmission of infection was assured. Poor uptake of varicella vaccine 
following licensing was primarily due to poor knowledge about availability of the vaccine and cost of the 
vaccine prior to funding. Resutts of these studies have been used to inform public heatth policy in relation 
to vaccine delivery to the community. 
Continuous review of the Australian National Immunisation Program is required to ensure optimal uptake, 
timely delivery and acceptability of vaccines. Studies in Chapter 5 outline new strategies to reduce the 
number 01 injections required to complete an immunisation schedule while ensuring optimal protection, to 
reduce the burden of disease in our community. 
The work presented in this thesis has supported the timely introduction of new vaccines with knowledge of 
the community's concerns and acceptance of these vaccines to direct optimal service delivery to achieve 
high vaccine uptake and reduction in the burden of disease for current and future generations. 
